The IRA provides Medicare beneficiaries with lower prescription drug costs and reduces overall drug spending by the federal government. For 2025, there is a positive change in the Medicare Part D benefit redesign for Medicare beneficiaries, which caps patient out-of-pocket drug costs at $2,000. In addition, the Medicare Prescription Payment Plan (MPPP) goes live in January 2025 as a new payment option for Medicare Part D beneficiaries, which will enable them to spread their out-of-pocket drug costs across the year.